Document 0107
 DOCN  M95A0107
 TI    Empirically treated Pneumocystis carinii pneumonia in Los Angeles,
       Chicago, and Miami: 1987-1990.
 DT    9510
 AU    Bennett CL; Horner RD; Weinstein RA; Kessler HA; Dickinson GM; Pitrak
       DL; Gilman SC; George WL; Cohn SE; Simberkoff MS; et al; Dept. of
       Medicine, Lakeside VA Medical Center, Chicago, IL 60611,; USA.
 SO    J Infect Dis. 1995 Jul;172(1):312-5. Unique Identifier : AIDSLINE
       MED/95318553
 AB    Many patients infected with the human immunodeficiency virus (HIV) with
       symptoms suggestive of pneumonia are treated empirically for
       Pneumocystis carinii pneumonia (PCP), although other bacterial
       infections (e.g., tuberculosis) and pulmonary Kaposi's sarcoma may cause
       identical symptoms. Empiric treatment for PCP may result in misdiagnosis
       and mistreatment. When the outcomes of cytologically confirmed versus
       empirically treated PCP cases were evaluated, the most important
       predictors of in-hospital mortality were severity of illness and use of
       bronchoscopy. Persons who did not undergo bronchoscopy had higher
       mortality rates than patients negative by bronchoscopy or cytologically
       confirmed as positive for PCP (22% vs. 11% vs. 14%, P < .01), although
       severity of illness and timing of anti-PCP medications did not differ
       significantly. Compared with cytologically confirmed cases, persons who
       did not have bronchoscopy were more likely to die than were
       bronchoscopy-negative patients (P < .05), after adjusting for severity
       of illness. Bronchoscopy use may have contributed to better outcomes for
       persons treated for HIV-related PCP.
 DE    Adult  AIDS-Related Opportunistic Infections/DIAGNOSIS/*EPIDEMIOLOGY/
       MORTALITY  Bronchoscopy  Chicago/EPIDEMIOLOGY  Comparative Study
       Diagnosis, Differential  Female  Florida/EPIDEMIOLOGY  Homosexuality,
       Male  Human  Los Angeles/EPIDEMIOLOGY  Male  Pneumonia, Pneumocystis
       carinii/DIAGNOSIS/*EPIDEMIOLOGY/MORTALITY  Risk Factors  Substance
       Abuse, Intravenous  Support, Non-U.S. Gov't  Support, U.S. Gov't,
       Non-P.H.S.  Support, U.S. Gov't, P.H.S.  Survival Rate  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).